All posts by PIER MARIA FORNASARI

PIER MARIA FORNASARI
2022-03-25

Most anti-PF4 antibodies in Covid-19 vaccine-induced immune thrombotic thrombocytopenia are transient

Platelet-activating anti-PF4 antibodies in VITT are transient in >90% of patients. Likely VITT patients can safely receive a second vaccination shot with an mRNA vaccine, independent of their VITT-antibody status. Vaccine-induced thrombotic thrombocytopenia (VITT) is triggered by vaccination against COVID-19 with adenovirus vector vaccines (ChAdOx1 nCoV-19; Ad26.COV2-S). In this observational study, were followed VITT patients

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-03-25

“Deltacron” a combination of the delta (AY.4) and BA.1 omicron variants named by the WHO as the BA.1 x AY.4 recombinant.

A combination of the delta (AY.4) and BA.1 omicron variants has been named by the World Health Organization as the BA.1 x AY.4 recombinant. First detected in France in January 2022, it has since picked up the nickname “deltacron”1 How does a recombinant emerge? Recombinants can emerge when multiple variants infect the same person at

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-03-23

American College of Cardiology Issues Clinical Guidance on CardioVascular Consequences of COVID-19

A new Expert Consensus Decision Pathway released by the ACC addresses the evaluation and management of some of the more common cardiovascular sequelae in adults with COVID-19. The Pathway, published March 16 in the Journal of the American College of Cardiology, specifically addresses myocarditis and other types of myocardial involvement, patient-centered approaches for long COVID, and

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-03-23

Huge step forward towards gene therapy and diagnosis for genetic eye disease

New opportunities towards gene therapy and diagnosis for the blinding eye disease, retinal dystrophy, may now become available following work done by the Eye Genetics Research Unit at Children’s Medical Research Institute. This work was published in the Journal of Personalized Medicine today. The team looked at the RPGR gene which is involved in maintaining

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-03-23

Kids with rare autoimmune disease antiphospholipid syndrome show these symptoms before blood clots 

Antiphospholipid syndrome is rare in adults and even less common among children.  Each year, around two of every 100,000 American adults receive a new diagnosis of antiphospholipid syndrome, or APS, an autoimmune disease known to cause inflammation and recurring, potentially fatal, blood clots. The number of children with APS is likely much smaller but unknown –

Read More

No Comments InRARE DISEASES
PIER MARIA FORNASARI
2022-03-18

Excess Neuropeptides Disrupt Lung Function in Infant Disease and COVID-19

UC San Diego study identifies lung neuroendocrine cells as drivers of developmental lung disease; similar mechanism may contribute to COVID-19 symptoms COVID-19 has put a spotlight on the pulmonary and nervous systems, but there is still much to learn about how they interact. Researchers at University of California San Diego School of Medicine recently explored

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-03-17

Cardiac damage as a side effect of CAR-T cell cancer therapy

CAR-T-cell cancer therapy uses special T-cells that are specifically directed towards tumor antigens, the so-called (CAR)-T-cells. These cells trigger a targeted immune response that helps the body recognize and fight cancer cells. But, like other cancer therapies, the treatment can cause unwanted side effects, such as affecting heart function. Scientists from the Medical Faculty of the University

Read More

No Comments InCAR-T